Free Trial
OTCMKTS:ZLDPF

Zealand Pharma A/S 2/20/2025 Earnings Report

Zealand Pharma A/S logo
$65.16 +1.80 (+2.84%)
As of 04/25/2025 12:35 PM Eastern

Zealand Pharma A/S EPS Results

Actual EPS
-$0.59
Consensus EPS
-$0.78
Beat/Miss
Beat by +$0.19
One Year Ago EPS
N/A

Zealand Pharma A/S Revenue Results

Actual Revenue
$1.30 million
Expected Revenue
$28.11 million
Beat/Miss
Missed by -$26.81 million
YoY Revenue Growth
N/A

Zealand Pharma A/S Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Zealand Pharma A/S' next earnings date is estimated for Wednesday, May 7, 2025, based on past reporting schedules.

Conference Call Resources

Zealand Pharma A/S Earnings Headlines

Zealand Pharma appoints Utpal Singh as CSO
May 1st: The Day That Could Change Everything
This may be one of the only profitable companies with Bitcoin infrastructure — real revenue, real momentum — that is publicly traded. The company generated over $144 million in revenue last year (top line for 2024) and $80.4 million in EBITDA — and it’s still not listed on a senior exchange. But that could be about to change.
See More Zealand Pharma A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email.

About Zealand Pharma A/S

Zealand Pharma A/S (OTCMKTS:ZLDPF), a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

View Zealand Pharma A/S Profile

More Earnings Resources from MarketBeat